Adding the measurement that the opening post says would settle it. Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part…
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did.
I was wrong about SELECT in a thread last spring and I would like to correct it publicly rather than quietly.
The error was in the units, which changed the conclusion by an order of magnitude. Setting out the corrected version, and the way I now check for that class of mistake.
Adding the measurement that the opening post says would settle it.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
I have changed my mind on this once already, so take it as current rather than settled.
Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Semaglutide formulation: what is in the licensed product besides the peptide
Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin semaglutide…
|
+29 | 35 | 4.4k | 1h |
|
Tracking semaglutide's approved indications across jurisdictions, dated
Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
|
+15 | 19 | 2.8k | 1d |
|
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
|
+15 | 19 | 4.4k | 13mo |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Putting the numbers in the first post, because a question about a…
|
2 | 63k | 5mo | |
|
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of c-cell question…
|
+61 | 65 | 1.3k | 22mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Preparing for an appointment: one page, three questions
Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. A question about how to describe something to a clinician rather…
|
+139 | 151 | 47k | 18mo |
|
Follow-up: Journal club: the retatrutide phase 2 obesity paper
On the subject in the title: Journal club: the retatrutide phase 2 obesity paper Working notes rather than a conclusion. A follow-up question about retatrutide phase 2 obesity paper that I did not know to ask…
|
+20 | 24 | 8.7k | 16mo |
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Trying to work out what would count…
|
+18 | 25 | 1.7k | 22mo |
|
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold?
The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…
|
+15 | 19 | 930 | 18mo |
|
Osteoarthritis and mechanical versus metabolic improvement — one year on
On the subject in the title: Osteoarthritis and mechanical versus metabolic improvement — one year on Working notes rather than a conclusion. Collecting what is known about Osteoarthritis and mechanical…
|
+52 | 56 | 8.1k | 15d |